[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Dientamoeba fragilis Infection- Market Insights, Epidemiology and Market Forecast 2028

July 2019 | 146 pages | ID: DFB37407B66EN
MIReports Co., Limited

US$ 5,980.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

'Dientamoeba fragilis Infection- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering:

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

Dientamoeba fragilis Infection Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Dientamoeba fragilis Infectionin the US, Europe, and Japan are also provided in the report.

Dientamoeba fragilis Infection Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Dientamoeba fragilis Infection Product Profiles & Analysis

This part of the Dientamoeba fragilis Infection report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Dientamoeba fragilis Infection Market Outlook

The Dientamoeba fragilis Infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Dientamoeba fragilis Infection Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Dientamoeba fragilis Infection Report Insights

Patient Population in Dientamoeba fragilis Infection

Therapeutic Approaches in Dientamoeba fragilis Infection

Dientamoeba fragilis Infection Pipeline Analysis

Dientamoeba fragilis Infection Market Size and Trends

Dientamoeba fragilis Infection Market Opportunities

Impact of upcoming Therapies in Dientamoeba fragilis Infection

Dientamoeba fragilis Infection Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Dientamoeba fragilis Infection Report Assessment

Current Treatment Practices in Dientamoeba fragilis Infection

Unmet Needs in Dientamoeba fragilis Infection

Detailed Dientamoeba fragilis Infection Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Dientamoeba fragilis Infection market

Organize sales and marketing efforts by identifying the best opportunities for Dientamoeba fragilis Infection market

To understand the future market competition in the Dientamoeba fragilis Infection market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

1 KEY INSIGHTS

2 DIENTAMOEBA FRAGILIS INFECTION MARKET OVERVIEW AT A GLANCE

2.1 Market Share (%) Distribution of Dientamoeba fragilis Infection in 2018
2.2 Market Share (%) Distribution of Dientamoeba fragilis Infection in 2028

3 DIENTAMOEBA FRAGILIS INFECTION: DISEASE BACKGROUND AND OVERVIEW

3.1 Introduction
3.2 Symptoms
3.3 Etiology
3.4 Risk Factor
3.5 Pathophysiology
3.6 Diagnosis
3.7 Treatment

4 EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Dientamoeba fragilis Infection in 7MM
4.3. Total Prevalent Patient Population of Dientamoeba fragilis Infection in 7MM – By Countries

5 EPIDEMIOLOGY OF DIENTAMOEBA FRAGILIS INFECTION BY COUNTRIES (2016-2028)

5.1 United States- Epidemiology (2016-2028)
  5.1.1 Assumptions and Rationale
  5.1.2 Prevalent/Incident Cases of Dientamoeba fragilis Infection in the United States
  5.1.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the United States
  5.1.4 Sex- Specific Cases of Dientamoeba fragilis Infection in the United States
  5.1.5 Diagnosed Cases of Dientamoeba fragilis Infection in the United States
  5.1.6 Treatable Cases of Dientamoeba fragilis Infection in the United States
5.2 EU5 Countries
  5.2.1 Germany
    5.2.1.1 Assumptions and Rationale
    5.2.1.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the Germany
    5.2.1.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the Germany
    5.2.1.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the Germany
    5.2.1.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the Germany
    5.2.1.6 Treatable Cases of the Dientamoeba fragilis Infection
  5.2.2 France
    5.2.2.1 Assumptions and Rationale
    5.2.2.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the France
    5.2.2.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the France
    5.2.2.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the France
    5.2.2.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the France
    5.2.2.6 Treatable Cases of the Dientamoeba fragilis Infection
  5.2.3 Italy
    5.2.3.1 Assumptions and Rationale
    5.2.3.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the Italy
    5.2.3.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the Italy
    5.2.3.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the Italy
    5.2.3.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the Italy
    5.2.3.6 Treatable Cases of the Dientamoeba fragilis Infection
  5.2.4 Spain
    5.2.4.1 Assumptions and Rationale
    5.2.4.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the Spain
    5.2.4.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the Spain
    5.2.4.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the Spain
    5.2.4.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the Spain
    5.2.4.6 Treatable Cases of the Dientamoeba fragilis Infection
  5.2.5 United Kingdom
    5.2.5.1 Assumptions and Rationale
    5.2.5.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the United Kingdom
    5.2.5.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the United Kingdom
    5.2.5.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the United Kingdom
    5.2.5.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the United Kingdom
    5.2.5.6 Treatable Cases of the Dientamoeba fragilis Infection
5.3 Japan
  5.3.1 Assumptions and Rationale
  5.3.2 Prevalent/Incident Cases of the of Dientamoeba fragilis Infection in the Japan
  5.3.3 Sub-Type Specific cases of Dientamoeba fragilis Infection in the Japan
  5.3.4 Sex- Specific Cases of the Dientamoeba fragilis Infection in the Japan
  5.3.5 Diagnosed Cases of the Dientamoeba fragilis Infection in the Japan
  5.3.6 Treatable Cases of the Dientamoeba fragilis Infection

6 CURRENT TREATMENT & MEDICAL PRACTICES

6.1 Treatment Algorithm
6.2 Treatment Guidelines

7 UNMET NEEDS

8 MARKETED PRODUCT

8.1 Drug A: Company
  8.1.1 Drug Description
  8.1.2 Mechanism of Action
  8.1.3 Clinical Trials Details
  8.1.4 Advantages & Disadvantages
  8.1.5 Safety and Efficacy
  8.1.6 Product Profile
8.2 Drug B: Company
  8.2.1 Drug Description
  8.2.2 Mechanism of Action
  8.2.3 Clinical Trials Details
  8.2.4 Advantages & Disadvantages
  8.2.5 Safety and Efficacy
  8.2.6 Product Profile
8.3 Drug C: Company
  8.3.1 Drug Description
  8.3.2 Mechanism of Action
  8.3.3 Clinical Trials Details
  8.3.4 Advantages & Disadvantages
  8.3.5 Safety and Efficacy
  8.3.6 Product Profile
8.4 Drug D: Company
  8.4.1 Drug Description
  8.4.2 Mechanism of Action
  8.4.3 Clinical Trials Details
  8.4.4 Advantages & Disadvantages
  8.4.5 Safety and Efficacy
  8.4.6 Product Profile
8.5 Drug E: Company
  8.5.1 Drug Description
  8.5.2 Mechanism of Action
  8.5.3 Clinical Trials Details
  8.5.4 Advantages & Disadvantages
  8.5.5 Safety and Efficacy
  8.5.6 Product Profile
8.6 : Company
  8.6.1 Drug Description
  8.6.2 Mechanism of Action
  8.6.3 Clinical Trials Details
  8.6.4 Advantages & Disadvantages
  8.6.5 Safety and Efficacy
  8.6.6 Product Profile
8.7 : Company
  8.7.1 Drug Description
  8.7.2 Mechanism of Action
  8.7.3 Clinical Trials Details
  8.7.4 Advantages & Disadvantages
  8.7.5 Safety and Efficacy
  8.7.6 Product Profile
8.8 : Company
  8.8.1 Drug Description
  8.8.2 Mechanism of Action
  8.8.3 Clinical Trials Details
  8.8.4 Advantages & Disadvantages
  8.8.5 Safety and Efficacy
  8.8.6 Product Profile

9 EMERGING DRUGS

9.1 Key Cross Competition
9.2 Emerging company
  9.2.1 Emerging Drug A: Company
    9.2.1.1 Other Development Activities
    9.2.1.2 Clinical Development
    9.2.1.3 Clinical Trials Information
    9.2.1.4 Safety and Efficacy
    9.2.1.5 Advantages and Disadvantages
    9.2.1.6 Product Profile
  9.2.2 Emerging Drug B: Company
    9.2.2.1 Other Development Activities
    9.2.2.2 Clinical Development
    9.2.2.3 Clinical Trials Information
    9.2.2.4 Safety and Efficacy
    9.2.2.5 Advantages and Disadvantages
    9.2.2.6 Product Profile
  9.2.3 Emerging Drug C: Company
    9.2.3.1 Other Development Activities
    9.2.3.2 Clinical Development
    9.2.3.3 Clinical Trials Information
    9.2.3.4 Safety and Efficacy
    9.2.3.5 Advantages and Disadvantages
    9.2.3.6 Product Profile
  9.2.4 Emerging Drug D: Company
    9.2.4.1 Other Development Activities
    9.2.4.2 Clinical Development
    9.2.4.3 Clinical Trials Information
    9.2.4.4 Safety and Efficacy
    9.2.4.5 Advantages and Disadvantages
    9.2.4.6 Product Profile
  9.2.5 Emerging Drug E: Company
    9.2.5.1 Other Development Activities
    9.2.5.2 Clinical Development
    9.2.5.3 Clinical Trials Information
    9.2.5.4 Safety and Efficacy
    9.2.5.5 Advantages and Disadvantages
    9.2.5.6 Product Profile

10 7MM MARKET ANALYSIS

10.1 7MM Market Size of Dientamoeba fragilis Infection
10.2 7MM Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection
10.3 7MM Market Sales of Dientamoeba fragilis Infection by Products

11 THE UNITED STATES MARKET OUTLOOK

11.1 Market Size of Dientamoeba fragilis Infection in United States
11.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in United States
11.3 Market Sales of Dientamoeba fragilis Infection by Products in United States
11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 COUNTRIES MARKET OUTLOOK

12.1 Market Size of Dientamoeba fragilis Infection in EU5
12.2 Market Size of Dientamoeba fragilis Infection in Germany
  12.2.1 Market Size of Dientamoeba fragilis Infection in Germany
  12.2.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in Germany
  12.2.3 Market Sales of Dientamoeba fragilis Infection by Products in Germany
  12.2.4 Analysis of Upcoming Therapies and Impact on the Market
12.3 Market Size of Dientamoeba fragilis Infection in France
  12.3.1 Market Size of Dientamoeba fragilis Infection in France
  12.3.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in France
  12.3.3 Market Sales of Dientamoeba fragilis Infection by Products in France
  12.3.4 Analysis of Upcoming Therapies and Impact on the Market
12.4 Market Size of Dientamoeba fragilis Infection in Italy
  12.4.1 Market Size of Dientamoeba fragilis Infection in Italy
  12.4.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in Italy
  12.4.3 Market Sales of Dientamoeba fragilis Infection by Products in Italy
  12.4.4 Analysis of Upcoming Therapies and Impact on the Market
12.5 Market Size of Dientamoeba fragilis Infection in Spain
  12.5.1 Market Size of Dientamoeba fragilis Infection in Spain
  12.5.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in Spain
  12.5.3 Market Sales of Dientamoeba fragilis Infection by Products in Spain
  12.5.4 Analysis of Upcoming Therapies and Impact on the Market
12.6 Market Size of Dientamoeba fragilis Infection in United Kingdom
  12.6.1 Market Size of Dientamoeba fragilis Infection in United Kingdom
  12.6.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in United Kingdom
  12.6.3 Market Sales of Dientamoeba fragilis Infection by Products in United Kingdom
  12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 THE JAPAN MARKET OUTLOOK

13.1 Market Size of Dientamoeba fragilis Infection in Japan
13.2 Percentage Share of Drugs Marketed for Dientamoeba fragilis Infection in Japan
13.3 Market Sales of Dientamoeba fragilis Infection by Products in Japan
13.4 Analysis of Upcoming Therapies and Impact on the Market

14 COST ANALYSIS OF DIENTAMOEBA FRAGILIS INFECTION

15 GENERIC COMPETITION IN DIENTAMOEBA FRAGILIS INFECTION MARKET

16 MARKET DRIVERS

17 MARKET BARRIERS

18 REPORT METHODOLOGY

18.1 Methodology/Research Approach
18.2 Data Source
  18.2.1 Secondary Sources
  18.2.2 Primary Sources


More Publications